je.st
news
BioCryst Pharmaceuticals Downgraded to Underperform at Bank of America
2015-11-16 05:33:57| Biotech - Topix.net
They presently have a $10.00 price target on the biotechnology company's stock, down from their previous price target of $12.00. Bank of America's price objective would indicate a potential upside of 3.95% from the stock's previous close.
Tags: america
bank
pharmaceuticals
downgraded
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||